A next-gen platform technology that disrupts the efficacy-toxicity trade-off with clinically validated polymer-drug conjugates for targeted chemotherapy and theranostics.
Superior Therapeutic Index
Sagitta® targeted delivery platforms are discovered to improve therapeutic index across a spectrum of payloads, addressing one of oncology’s most persistent challenges: The efficacy-toxicity trade-off.
SUPERIOR THERAPEUTIC INDEX
Sagitta® targeted delivery platforms are discovered to improve therapeutic index across a spectrum of payloads, addressing one of oncology’s most persistent challenges:The efficacy-toxicity trade-off.
RS Research Announces Successful Completion of Phase 1 Clinical Trial of RS-0139 in Solid Tumors
RS Research, a biotechnology company developing smart nanomedicines for oncology, has announced the successful completion of the Phase 1 clinical trial of its lead investigational candidate, RS-0139, in patients with solid tumors.
RS Research Co-Founder Prof. Rana Sanyal won the European Prize for Women Innovators
The European Commission announced the winners of the 10th edition of the European Prize for Women Innovators during the opening of Research & Innovation Week in Brussels. In the leading “Women Innovators” category, the award was presented to RS Research Co-Founder Prof. Rana Sanyal in recognition of her outstanding achievements and impact in the field of biotechnology.
RS Research was featured in the cover story of Forbes Türkiye
Recognizing the company as a leading success story in translating scientific research into real-world therapeutic impact, RS Research’s accomplishments in developing targeted therapies were on the cover of Forbes Türkiye September 2025 issue.
